There is no transparancy at all! How is the J&J study evolving? Are all participants enrolled, what are the primary and secondary endpoints? Is the company going for FDA approval for only rotator cuff or other tendon problems as well? Why all these little studies? What's the use of them? Why not a single progression in capital markets like China, Japan although there is so much experience in the board of directors? Cash is a big problem: they should raise 100m AUD to be financial strong. Why doesn't the company ask to be listed on the Nasdaq to get more attention internationally? Before there will be a substantial rise in share price, if that would happen (maybe after FDA approval of celgro AND ortho-ATI), all the warrants need to be converted. That is a BIG barrier to overcome, just look it up, you'll be negatively surprised I ask for five things: transparancy, capital raise, reverse split after the capital raise, listing on Nasdaq, and Finally execution of penetration in the Japanese and Chinese market.
- Forums
- ASX - By Stock
- J&J Study?
There is no transparancy at all! How is the J&J study evolving?...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OCC (ASX) to my watchlist
(20min delay)
|
|||||
Last
46.0¢ |
Change
0.005(1.10%) |
Mkt cap ! $96.40M |
Open | High | Low | Value | Volume |
45.5¢ | 46.5¢ | 45.5¢ | $87.13K | 189.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 271 | 46.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
46.5¢ | 21507 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 271 | 0.460 |
3 | 9722 | 0.450 |
1 | 22727 | 0.440 |
2 | 41207 | 0.430 |
2 | 12500 | 0.415 |
Price($) | Vol. | No. |
---|---|---|
0.465 | 21507 | 1 |
0.470 | 75812 | 5 |
0.475 | 15000 | 3 |
0.480 | 159375 | 8 |
0.485 | 100000 | 1 |
Last trade - 15.40pm 04/10/2024 (20 minute delay) ? |
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
OCC (ASX) Chart |